I like their current focus on MDMA/MDMA analogues as well. At this stage better clinical evidence than psilocybin. This is mentioned in the Interim report to the TGA. there’s a large phase 3 trial in the USA for MDMA for PTSD which will wrap up soon and is by far the most advanced piece of work in the whole psychedelic field,
It’s actually not unfeasible TGA will downschedule MDMA prior to psilocybin.
I like their current focus on MDMA/MDMA analogues as well. At...
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.31M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 533841 | 3.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.7¢ | 70000 | 1 |
View Market Depth
| Last trade - 09.41am 16/08/2024 (20 minute delay) ? |
| EMD (ASX) Chart |
Day chart unavailable